A5068468096- Schizophrenia research and treatment
- Stress Responses and Cortisol
- Neuropeptides and Animal Physiology
- Bipolar Disorder and Treatment
- Neurotransmitter Receptor Influence on Behavior
- Atrial Fibrillation Management and Outcomes
- Neuroendocrine regulation and behavior
- Treatment of Major Depression
- Mental Health and Psychiatry
- Receptor Mechanisms and Signaling
- Tryptophan and brain disorders
- Electroconvulsive Therapy Studies
- Pediatric Pain Management Techniques
- Parkinson's Disease Mechanisms and Treatments
- Peripheral Nerve Disorders
- Pain Mechanisms and Treatments
- Botulinum Toxin and Related Neurological Disorders
- Parkinson's Disease and Spinal Disorders
- Hair Growth and Disorders
- Biochemical effects in animals
- Diet and metabolism studies
- Pharmaceutical Practices and Patient Outcomes
- Neuroscience and Neuropharmacology Research
- Autoimmune Bullous Skin Diseases
- Heart Failure Treatment and Management
Universidad de Murcia
2013-2025
Santa Lucía University General Hospital
2019-2025
Universidad Católica San Antonio de Murcia
2023-2025
Instituto Murciano de Investigación Biosanitaria
2023
Hospital Reina Sofía de Murcia
2019-2022
Hospital Universitario Reina Sofía
2018-2021
Background LAIs with longer dosing intervals appear to be associated improved clinical outcomes and added real-world benefits in the management of schizophrenia. Paliperidone palmitate six-monthly (PP6M) LAI provides longest interval, twice-yearly dosing, among all currently available LAIs. In trials PP6M was found non-inferior preventing relapses patients schizophrenia compared three monthly formulation (PP3M) though real world data remain limited. Therefore, aim this study evaluate...
Introduction: Time tracking of acute stroke assistance is crucial for treatment goals. Resources availability varies among centers. We aim to assess a low-cost mobile app's impact on collecting times in traditional hospital. Patients and Methods: Neurology consultants residents tested the application prototype voluntarily from July 14 September 30, 2021. A prospective observational study, based pre- post-implementation anonymous satisfaction surveys, was designed. While primary objective not...
Background Extinction period of positive affective memory drug taking and negative withdrawal, as well the different response men women might be important for clinical treatment addiction. We investigate role corticotropin releasing factor receptor type one (CRF1R) male female mice in expression extinction aversive memory. Methodology/Principal Finding used genetically engineered lacking functional CRF1R. The animals were rendered dependent on morphine by intraperitoneally injection...
To date, only a few studies compared some long-acting injectables (LAIs) antipsychotics showing similar symptom improvement, relapse rates and adherence to treatment. We evaluated the use of LAIs [aripiprazole-1-month (A1M); paliperidone-1-month 3-month (PP1M PP3M) biweekly (2w)-LAIs] their corresponding oral formulations through (1) number hospital re-admissions, (2) documented suicidal behaviour/attempts (3) concomitant benzodiazepines, biperiden. A total 277 patients, ≥18 years old, were...
Stress induces the release of peptide corticotropin-releasing factor (CRF) into ventral tegmental area (VTA), and also increases dopamine (DA) levels in brain regions receiving dense VTA input. Since role stress drug addiction is well established, present study examined possible involvement CRF1 receptor interaction between morphine withdrawal catecholaminergic pathways reward system. The effects naloxone-precipitated on signs withdrawal, hypothalamo-pituitary-adrenocortical (HPA) axis...
The negative affective states of withdrawal involve the recruitment brain and peripheral stress circuitry [noradrenergic activity, induction hypothalamic-pituitary-adrenocortical (HPA) axis activation heat shock proteins (Hsps)]. Corticotropin-releasing factor (CRF) pathways are important mediators in symptoms opioid withdrawal. We performed a series experiments to characterize role CRF₁ receptor response systems morphine its effect heart using genetically engineered mice lacking functional...
Corticotropin-releasing factor (CRF) acts as neuro-regulator of the behavioral and emotional integration environmental endogenous stimuli associated with drug dependence. Thioredoxin-1 (Trx-1) is a functional protein controlling redox status several proteins, which involved in addictive processes. In present study, we have evaluated role CRF1 receptor (CRF1R) rewarding properties morphine by using conditioned place preference (CPP) paradigm. We also investigate effects CRF1R antagonist,...
This study examined the involvement of brain stress system in reinforcing effects morphine. One group mice was conditioned to morphine using place preference (CPP) paradigm and other received a home-cage (non-conditioned). Adrenocorticotropic hormone corticosterone levels were measured by radioimmunoassay; phospho (p) CREB expression number corticotropin-releasing factor (CRF) neurons fibres immunohistochemistry different areas. We observed that CRF paraventricular nucleus (PVN) increased...
Clozapine, an antipsychotic developed in 1958, is considered the gold standard and treatment of choice treatment-resistant schizophrenia despite its side effects 40–70% these patients not responding to clozapine. In last decade, new antipsychotics, such as paliperidone palmitate (PP), have emerged well long acting-injectable (LAI) formulations, available PP-1-monthly (PP1M) newest PP-3-montlhy (PP3M). Despite having shown a similar efficacy others antipsychotics for schizophrenia, that PP3M...
The aim of the present study was to evaluate use oral vs. long-acting injectables (LAIs) antipsychotics, as well as, compare effectiveness different LAI antipsychotics [aripiprazole-1-month, paliperidone-1-month (PP1M), paliperidone-3-month (PP3M) and risperidone injectable (RLAI)] in patients diagnosed with borderline personality disorder (BPD), by evaluating following clinical outcomes: (1) number hospital admissions; (2) documented suicidal behaviour/attempts; (3) concomitant treatments,...
We aimed to evaluate and compare the use of paliperidone palmitate-1 3-month (PP1M, PP3M), aripiprazole 1-month (A1M) risperidone-LAI (RLAI) LAIs, using following clinical outcomes: (1) number hospital admissions, (2) bed days, (3) concomitant treatments, including benzodiazepines, oral antipsychotics, biperiden. For that purpose, we designed a cross-sectional study, from 2015-2021, based on non-institutionalized population accessing care mental health services in Spain UK who were...
Paliperidone palmitate 6-monthly (PP6M) is the first long-acting antipsychotic injectable (LAI) to allow for only two medication administrations per year, though there presently limited insight into its effectiveness and potential added value in real clinical practice conditions.To present our ongoing study draw preliminary data on patient characteristics initiating PP6M adherence during year of treatment.The paliperidone 2 (P2Y) a 4-year, multicentre, prospective mirror-image pragmatic...
Despite comprehensive study, the aetiology of stroke is not identified in 35% cases. We conducted a study to assess diagnostic capacity N-terminal pro-B-type natriuretic peptide (NT-proBNP) identification ischaemic cardioembolic origin. The secondary purpose was evaluate prognostic value NT-proBNP for predicting 90-day all-cause mortality. designed prospective observational including patients hospitalised due between March 2019 and 2020. Blood samples were collected on admission emergency...
We report a 49-year-old patient suffering from spastic paraplegia with novel heterozygous mutation and analyzed the levels of heat shock proteins (hsp)-27, dopamine (DA), its metabolites in their cerebrospinal fluid (CSF). The hsp27 protein concentration patient’s CSF was assayed by an ELISA kit, while DA CSF, 3,4-dihydroxyphenylacetic acid (DOPAC), Cys-DA, Cys-DOPA were measured HPLC. Whole exome sequencing demonstrated SPG-11 c.1951C>T SYNJ1 c.2614G>T mutations, both recessive. DOPAC...